Japan Medical Dynamic Marketing, Inc.

Japan Medical Dynamic Marketing, Inc.

7600.T
Japan Medical Dynamic Marketing, Inc.JP flagTokyo Stock Exchange
878.00
JPY
-11.00
- -
23.14BMarket Cap
Japan Medical Dynamic Marketing, Inc.
7600.T
(Tokyo Stock Exchange)

Recent

price

878.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
TTM
FRC
360.19
- -
307.4
357.48
448.02
492.22
515.73
560.89
633.64
685.11
634.41
727.46
808.6
880.5
951.71
907.78
464.35
Revenue per Share
2.69
- -
-15.04
10.83
-14.8
30.25
42.78
53.99
75.17
82.02
63.09
80.95
54.03
48.31
-17.5
9.99
34.64
Basic EPS, GAAP
34.22
- -
2.33
-67.55
34.33
-1.09
36.37
58.54
10.36
35.83
46.54
57.86
33.04
11.49
-23.49
-68
- -
Free Cash Flow per Basic Share
4.98
- -
5.02
5.01
5.02
5.01
6.03
7.01
7.99
9.02
10.02
11
12.04
13.07
14.06
15.07
- -
Dividend per Share
337.75
- -
305.98
311.82
292.02
317.28
354.46
401.8
468.94
542.06
595.34
665.26
708.04
744.05
710.68
706.73
748.72
Book Value per Share
432.15
- -
405.68
412.27
405.43
423.92
461.11
499.15
570.09
633.12
699.62
803.49
873.91
964.33
921.28
948.8
938.58
Tangible Book Value per Share
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
26
Basic Weighted Avg Shares
9,531
- -
8,134
9,459
11,855
13,025
13,630
14,808
16,729
18,083
16,738
19,193
21,308
23,178
25,114
23,917
12,225
Sales/Revenue/Turnover
21.02
- -
-1.87
6.99
10.93
13.11
14.01
13.81
13.36
14.62
12.96
13.87
9.5
7.54
6.2
2.4
9.24
Operating Margin (%)
826
- -
805
927
1,102
894
930
1,015
1,162
1,389
1,389
1,421
1,550
1,595
1,671
1,614
689
Depreciation Expense
71
- -
-398
287
-392
801
1,131
1,425
1,985
2,165
1,665
2,136
1,424
1,272
-462
263
912
Net Income, GAAP
58.01
- -
- -
30.66
138.77
33.88
28.24
17.02
7.93
16.37
17.38
22.11
18.88
20.24
- -
44.31
13.44
Effective Tax Rate (%)
0.75
- -
-4.89
3.03
-3.3
6.15
8.3
9.63
11.86
11.97
9.94
11.13
6.68
5.49
-1.84
1.1
7.46
Profit Margin (%)
5,641
- -
5,322
6,604
7,075
6,855
7,493
7,818
9,660
12,119
13,478
15,147
16,348
17,552
16,608
17,179
17,090
Working Capital
378
- -
1,751
2,710
2,221
1,912
1,598
837
1,615
2,408
2,059
1,259
790
294
112
938
182
LT Debt
11,568
- -
10,838
11,052
10,854
11,331
12,288
13,263
15,234
16,993
18,713
21,491
23,292
25,604
24,741
25,428
24,889
Total Equity
5.01
- -
- -
2.84
-2.94
6.58
7.63
9.26
10.85
10.73
8.27
9.08
6.69
5.28
- -
1.07
3.62
Return on Invested Capital (%)
0.8
- -
- -
2.89
-3.28
6.34
8.15
9.83
12.85
12.46
9
11.22
7.1
6.04
- -
1.56
4.17
Return on Capital (%)
0.79
- -
-9.83
3.51
-4.9
9.93
12.73
14.27
17.27
16.22
11.09
12.84
7.86
6.65
-2.41
1.41
4.75
Return on Common Equity (%)

Capital Structure

FRC

in mil. unless spec.
Mar'24
Jun'25
Sep'25
ST Debt
1,200
- -
2,264
LT Borrowings
260
- -
167
LT Finance Leases
35
- -
15
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
26
- -
26
Market Capitalization
19,331
18,008
18,929

Working Capital

FRC

in mil. unless spec.
Mar'24
Jun'25
Sep'25
Total Current Assets
21,583
- -
21,565
Cash, Cash Equivalents & STI
2,322
- -
2,260
Accounts Receivable, Net
5,915
- -
5,357
Inventories
13,092
- -
13,407
Total Current Liabilities
4,031
- -
4,475
Payables & Accruals
- -
- -
- -
ST Debt
1,200
- -
2,264
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
8.54%
6.51%
2.77%
Free Cash Flow
-336.32%
-39.97%
189%
Net Income, GAAP
-21.65%
-61.8%
-156.98%
Sales/Revenue/Turnover
6.5%
7.61%
-4.77%
Total Cash Common Dividend
11.67%
8.46%
6.96%

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
5,403
5,550
6,042
6,184
23,178
2025
- -
- -
- -
- -
25,114
2026
- -
- -
- -
- -
23,917

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
6.74
- -
- -
- -
48.31
2025
- -
- -
- -
- -
-17.5
2026
- -
- -
- -
- -
9.99

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
13.07
2025
- -
- -
- -
- -
14.06
2026
- -
- -
- -
- -
15.07
Business
Japan Medical Dynamic Marketing, Inc. engages in the development, manufacture, import, and sale of advanced medical equipment primarily for orthopedic surgery. Its core product offerings include trauma devices, joint prostheses, spinal fixation devices, and artificial bone fillers. The company supplies its products mainly to medical professionals and major hospitals across Japan, operating through its Japan segment, which imports and sells materials for osteosynthesis, artificial joints, and spinal fixation devices. Additionally, its America segment handles the development, manufacture, and sales of these medical products in North America. Founded in 1973 and headquartered in Tokyo, Japan, Japan Medical Dynamic Marketing is recognized as a leading company in the Japanese orthopedic medical device market. Recent strategic changes include a significant organizational restructuring to a business division system as of April 1, 2024, designed to strengthen the sales structure. The company has introduced the Trivicta Hip Stem, a new artificial hip joint product, to boost growth in the hip joint segment. Procurement shifts occurred with some key products sourcing moving from the U.S. to Japan to mitigate exchange rate risks and reduce costs. Furthermore, Japan Medical Dynamic Marketing began supplying its BKS TriMax medical instruments to the U.S. market starting February 2024. These moves reflect the company's efforts to enhance procurement capabilities, expand product offerings, and increase its presence in both domestic and international markets. Japan Medical Dynamic Marketing operates mainly in the healthcare industry, focusing on the medical device segment associated with orthopedic surgery. Its target market comprises hospitals, orthopedic surgeons, and healthcare providers in Japan and the U.S. The company also leverages its dual role as a manufacturer and a trading company to offer a comprehensive product range and respond flexibly to dynamic market needs. Its subsidiary operations support these activities in North America as part of its expansion and product development strategy. The company’s longstanding presence since its founding and continuous innovation in product development underscores its commitment to contributing to medical care and advancing orthopedic treatment technologies.